TRACERS Sample Clauses

TRACERS. When a biomarker with favorable characteristics is selected, this biomarker can be tar- geted using various types of (NIR) fluorescent tracers, consisting of a targeting vehicle and a (NIR) fluorophore (e.g. ZW800-1, IRDye800CW, Cy5). Different types of vehicles can be used, ranging from (therapeutic) monoclonal antibodies, antibody fragments to larger and smaller peptides mimicking the natural receptor ligands such as GE-137 or EMI-137 for c-MET (HGFR), folate for FR-α and the RGD sequence for imaging of vari- ous integrins [24-26]. For tumor imaging, important characteristics are efficient tumor penetration and low affinity for surrounding normal tissue and, depending on the ap- plication, a reasonable half-life (hours)in the circulation [27]. Monoclonal antibodies are already widely investigated and show specific and sensitive tumor binding characteris- tics. Because of their large size (150 kDa), injected antibodies possess prolonged blood half-life times (up-to 72h) resulting in early high background signals and subsequently large imaging windows (24-96h). When shorter elimination times are desired, smaller vehicles like F(ab)s (50 kDa), scFv (27 kDa), nanobodies (27kDa) and/or small peptides (1-2 kDa) can be used. In general, the use of smaller tracers increase the tumor pen- etration capacity of the compound, decrease liver uptake, reduce background signals and shorten the time between injection and imaging. Nevertheless, all these tracers vary considerably in physical characteristics like size, affinity, charge, and possibility to conjugate to (fluorescent) dyes. Therefore, they offer specific advantages and disadvan- tages for the purpose of achieving appropriate tumor targeting. Various clinical grade (NIR) fluorophores are available that can be conjugated to tumor-specific vehicles like IRDye800CW and ZW800-1 [28, 29]. The development of validated NIR fluorescent imaging systems is dependent on the (clinical) availability of NIR fluorescent tracers and vice versa. Therefore, presently, novel imaging systems are only sparsely developed and clinically introduced. Due to the lack of performance standards for these imaging systems, at present, the combination with a tracer is of major importance for successful functioning and evaluation [30, 31]. For example, the failure of a tracer to delineate tumors could be interpreted as a failure of the tracer, when in fact the unqualified device was simply not sensitive enough for detection. We mainly used a ...
Sample 1
AutoNDA by SimpleDocs

Related to TRACERS

  • COVID-19 Vaccine Passports Pursuant to Texas Health and Safety Code, Section 161.0085(c), Contractor certifies that it does not require its customers to provide any documentation certifying the customer’s COVID-19 vaccination or post-transmission recovery on entry to, to gain access to, or to receive service from the Contractor’s business. Contractor acknowledges that such a vaccine or recovery requirement would make Contractor ineligible for a state-funded contract.

  • Users There is no limit to the number of users who can access the Software. You can invite any person You wish to access the Software.

  • Operators Any and all Operators of the Equipment shall be duly experienced, trained and qualified to operate Equipment of this type. Although We may, from time to time, recommend certain qualified Operators with whom We are familiar, We do not supply Operators. You must supply and employ any Operator who operates the Equipment (even if the Operator is the owner of the Equipment or owner of a company that owns the Equipment) and that Operator shall be deemed to be Your employee and acting under Your supervision or control for all purposes and shall be covered as an insured on all of Your applicable insurance policies.

  • End Users Customer will control access to and use of the Products by End Users and is responsible for any use of the Products that does not comply with this Agreement.

  • Samples The Contractor shall submit the following samples of Materials and relevant information to the Authority’s Engineer for pre-construction review: (a) manufacturer's test reports and standard samples of manufactured Materials; and (b) samples of such other Materials as the Authority’s Engineer may require.

  • Data Storage Where required by applicable law, Student Data shall be stored within the United States. Upon request of the LEA, Provider will provide a list of the locations where Student Data is stored.

  • Influenza Vaccine Upon recommendation of the Medical Officer of Health, all employees shall be required, on an annual basis to be vaccinated and or to take antiviral medication for influenza. If the costs of such medication are not covered by some other sources, the Employer will pay the cost for such medication. If the employee fails to take the required medication, she may be placed on an unpaid leave of absence during any influenza outbreak in the home until such time as the employee has been cleared by the public health or the Employer to return to the work environment. The only exception to this would be employees for whom taking the medication will result in the employee being physically ill to the extent that she cannot attend work. Upon written direction from the employee’s physician of such medical condition in consultation with the Employer’s physician, (if requested), the employee will be permitted to access their sick bank, if any, during any outbreak period. If there is a dispute between the physicians, the employee will be placed on unpaid leave. If the employee gets sick as a reaction to the drug and applies for WSIB the Employer will not oppose the application. If an employee is pregnant and her physician believes the pregnancy could be in jeopardy as a result of the influenza inoculation and/or the antiviral medication she shall be eligible for sick leave in circumstances where she is not allowed to attend at work as a result of an outbreak. This clause shall be interpreted in a manner consistent with the Ontario Human Rights Code.

  • API If the Software offers integration capabilities via an API, your use of the API may be subject to additional costs or Sage specific policies and terms and conditions (which shall prevail in relation to your use of the API). You may not access or use the API in any way that could cause damage to us or the Software, or in contravention of any applicable laws. We reserve the right in our sole discretion, to: (i) update any API from time to time; (ii) place limitations around your use of any API; and (iii) deny you access to any API in the event of misuse by you or to otherwise protect our legitimate interests.

  • Radiation Therapy/Chemotherapy Services This plan covers chemotherapy and radiation services. This plan covers respiratory therapy services. When respiratory services are provided in your home, as part of a home care program, durable medical equipment, supplies, and oxygen are covered as a durable medical equipment service.

  • Vaccinations Contractor understands, acknowledges, and agrees that, pursuant to Article II of the General Appropriations Act, none of the General Revenue Funds appropriated to the Department of State Health Services (DSHS) may be used for the purpose of promoting or advertising COVID-19 vaccinations in the 2024-25 biennium. It is also the intent of the legislature that to the extent allowed by federal law, any federal funds allocated to DSHS shall be expended for activities other than promoting or advertising COVID-19 vaccinations. Contractor represents and warrants that it is not ineligible, nor will it be ineligible during the term of this Contract, to receive appropriated funding pursuant to Article II.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!